Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients.
ADP, adenosine diphosphate
CAD, coronary artery disease
COVID-19
COVID-19, coronavirus disease-2019
CRP, C-reactive protein
GPA, granulocyte–platelet aggregates
HS, healthy subject
IL, interleukin
IL-6
IL-6R, interleukin-6 receptor
LMWH, low-molecular-weight heparin
MPA, monocyte–platelet aggregates
MV, microvesicle
NO, nitric oxide
NOS, nitric oxide synthase
PGI2, prostacyclin
PLA, platelet–leukocyte aggregates
PS, phosphatidylserine
SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2
TF, tissue factor
antiplatelet drugs
circulating microvesicles
platelet activation
tissue factor
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
03
11
2020
revised:
15
12
2020
accepted:
15
12
2020
pubmed:
3
3
2021
medline:
3
3
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
The authors hypothesized that the cytokine storm described in COVID-19 patients may lead to consistent cell-based tissue factor (TF)-mediated activation of coagulation, procoagulant microvesicles (MVs) release, and massive platelet activation. COVID-19 patients have higher levels of TF
Identifiants
pubmed: 33649738
doi: 10.1016/j.jacbts.2020.12.009
pii: S2452-302X(20)30548-9
pmc: PMC7904280
doi:
Types de publication
Journal Article
Langues
eng
Pagination
202-218Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
This work was supported by a grant from Italian Ministry of Health (Ricerca Corrente Reti 2020- RCR-2020-23670065, to Prof. Camera). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
J Virol. 2016 Oct 14;90(21):9683-9692
pubmed: 27535047
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1690-6
pubmed: 12855480
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Thromb Haemost. 2015 Aug 31;114(3):478-89
pubmed: 25904241
N Engl J Med. 1984 Apr 26;310(17):1065-8
pubmed: 6231483
J Infect Dis. 1999 Jul;180(1):176-86
pubmed: 10353876
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232226
Ann Rheum Dis. 2016 Aug;75(8):1511-20
pubmed: 26819099
Front Microbiol. 2015 Jan 05;5:733
pubmed: 25601858
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
J Thromb Thrombolysis. 2020 Aug;50(2):287-291
pubmed: 32445064
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Basic Clin Pharmacol Toxicol. 2020 Aug;127(2):67-80
pubmed: 31495057
J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):841-52
pubmed: 24152848
Am J Clin Pathol. 2020 May 5;153(6):725-733
pubmed: 32275742
J Med Virol. 2021 Jan;93(1):46-47
pubmed: 32484915
Pharmacol Res. 2020 Aug;158:104950
pubmed: 32450344
PLoS Med. 2008 Oct 21;5(10):e203
pubmed: 18942885
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
J Thromb Haemost. 2006 Jun;4(6):1323-30
pubmed: 16706978
Br J Haematol. 1999 Aug;106(2):391-9
pubmed: 10460597
Blood. 2010 Dec 2;116(23):5076-7
pubmed: 21127189
J Intensive Care. 2015 Jan 07;3(1):2
pubmed: 25705427
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Hypertens. 2018 Jun;36(6):1360-1371
pubmed: 29470366
Thromb Res. 2020 Jul;191:9-14
pubmed: 32353746
Front Med (Lausanne). 2018 Apr 30;5:121
pubmed: 29761104
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):340-6
pubmed: 22156911
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Semin Thromb Hemost. 2015 Oct;41(7):737-46
pubmed: 26408918
Kidney Int Rep. 2020 Mar 27;5(5):563-565
pubmed: 32292865